Safety of Mesentery-embedding Surgery in Patients With Ileocolic Crohn's Disease on Biotherapy

Inclusion Criteria

• •The patient must have given their free and informed consent and signed the consent form
• •The patient must be a member or beneficiary of a health insurance plan
• •Patient with histologically proven Crohn's disease
• •Patient who has undergone ileocolic resection and whose disease site is accessible to endoscopic follow-up (first or repeat operation)
• •Patient on anti-TNF α: infliximab or adalimumab (ECCO 2014 recommendation), vedolizumab, ustkinumab, or other biotherapy (e.g. risankizumab)
• •Patient able to understand, write and read French